Apyx Medical Corporation (APYX) Company Overview

What does Apyx Medical Corporation do?

Apyx Medical Corporation is a Nasdaq-listed surgical aesthetics company whose technology delivers controlled heat to tissue using radiofrequency energy and helium plasma. Its principal brands are Renuvion for cosmetic surgery, J-Plasma for hospital applications and the AYON Body Contouring System. The company’s investor-relations materials describe a physician-focused model: customers buy capital equipment and use proprietary disposable handpieces during procedures.

Which products and customers define the company?

The helium-plasma platform combines a generator, helium gas and a single-use handpiece. Radiofrequency energy ionizes the helium so a surgeon can apply localized heat. Renuvion addresses aesthetic tissue contraction; J-Plasma serves hospital applications. The official AYON product page describes an integrated platform spanning infiltration, aspiration, fat transfer, electrosurgery and Renuvion tissue contraction.

Apyx sells directly in the United States and uses distributors in many international markets. Direct selling supports closer training and pricing control; distributors extend reach with less infrastructure but can produce lower margins and less direct control over demand.

How does Apyx Medical make money?

Apyx has two reportable segments. Surgical Aesthetics sells generators, AYON systems and recurring handpieces; OEM develops and manufactures electrosurgical products for third parties. The 2025 Form 10-K makes Surgical Aesthetics the strategic center, while management expects OEM revenue to decline as resources shift toward aesthetics.

Why are disposable handpieces economically important?

The installed-base logic is central: each generator or AYON placement can produce repeat proprietary-handpiece purchases. Apyx sold about 84,000 handpieces in FY2025, and handpiece revenue was about half of Surgical Aesthetics revenue as AYON increased capital-equipment sales. Q1 2026 volume reached roughly 26,000 units, and handpieces again represented more than half of segment revenue.

Why is AYON strategically important to Apyx?

AYON moves Apyx beyond a stand-alone tissue-contraction tool toward a broader workflow platform. Combining functions that may otherwise require separate equipment can increase placement value, strengthen the sales proposition and deepen the link between installed systems and recurring consumables.

What did the 2026 clearance add?

AYON initially received FDA 510(k) clearance in May 2025 and entered full U.S. commercial launch in September 2025. In May 2026, Apyx received an expanded FDA clearance for power liposuction. The added modality uses a reciprocating cannula intended to make fat removal more efficient and reduce surgeon effort and operating-room time. Management began with a limited commercial launch so training and utilization practices could be refined before broader scaling.

What does Apyx Medical’s latest quarter show?

The quarter ended March 31, 2026 provided early evidence that AYON, international Renuvion demand and handpiece volume can lift revenue while costs remain controlled. The company’s Q1 2026 results showed 32.4% revenue growth and a 63.5% gross margin. Apyx remained loss-making, but the operating loss narrowed materially.

Which lines drove the improvement?

How important was international growth?

International revenue rose 62.9% to $4.4 million, helped by South Korea and broader Renuvion sales; domestic revenue increased 20.3% to $8.1 million. The diversification is positive, but distributor economics and tariffs that began affecting Apyx in late 2025 can pressure margin.

Which turning points shaped Apyx Medical today?

Apyx evolved from electrosurgical engineering toward a focused surgical-aesthetics platform. The decisive events changed recurring revenue, regulatory scope, distribution or product breadth.

1. 1982
   The company was incorporated, establishing the electrosurgical engineering base that later supported both OEM products and proprietary energy devices.
2. 2012
   The helium-plasma platform received its initial FDA clearance, creating the technical foundation for Renuvion and J-Plasma.
3. 2014–2015
   Apyx added a direct U.S. sales force and pursued commercialization in cosmetic surgery, moving closer to physicians and away from dependence on indirect channels.
4. 2018
   The company sold core electrosurgical assets and entered a long-term supply relationship, leaving OEM revenue while sharpening the strategic emphasis on advanced energy and aesthetics.
5. 2023
   Apyx One reached full commercial launch, integrating Renuvion with monopolar and bipolar energy and reinforcing the platform approach.
6. 2025
   AYON received initial FDA clearance and launched commercially in September; Renuvion also entered China, while South Korea approval expanded the international footprint.
7. 2026
   Power-liposuction clearance broadened AYON’s function set, while Q1 results showed faster Surgical Aesthetics growth and management raised FY2026 revenue guidance.

What did the 2024 restructuring change?

The November 2024 restructuring reduced the U.S. workforce by nearly 25% and targeted approximately $4.3 million of annualized savings. FY2025 operating expenses fell to $39.5 million. The trade-off is straightforward: Apyx needs commercial investment to scale AYON and international markets, but expenses cannot rebuild faster than gross profit while debt interest remains substantial.

What gives Apyx a competitive advantage?

Apyx’s advantage is not scale. It is a narrower combination of helium-plasma intellectual property, regulatory clearances, clinical evidence, surgeon familiarity and proprietary consumables. The 2025 filing listed 102 issued U.S. and foreign patents plus 32 pending applications.

How durable are the moat components?

Who are the most relevant competitors?

Competition includes energy devices, noninvasive skin-tightening platforms, liposuction systems and broader aesthetics vendors. Apyx names Solta Medical and MicroAire Surgical Instruments among major power-liposuction manufacturers, while larger rivals can offer broader catalogs and financing.

How financially strong is Apyx Medical?

Apyx has near-term liquidity but is not financially self-sustaining. FY2025 revenue was $52.8 million, gross margin was 62.5%, operating loss was $6.4 million and net loss attributable to stockholders was $11.2 million. Operating cash use plus $1.1 million of capital spending produced simple free cash flow of about negative $9.1 million.

Why does gross margin matter so much?

At Q1 2026 revenue of $12.5 million, gross profit of $7.9 million was still below operating expenses of $8.8 million. A higher-margin revenue mix, more recurring handpieces and expense discipline can close that gap. Conversely, distributor mix, tariffs, discounting or product costs could delay operating break-even even if revenue grows.

How significant are debt and liquidity?

The Q1 2026 Form 10-Q states that the company complied with its credit covenants. Those include a $52.4 million year-end 2026 trailing Surgical Aesthetics revenue target, a $45.0 million maximum operating-expense target and a $3.0 million minimum cash requirement. Compliance is important because additional equity could dilute shareholders, while more debt would add service costs and restrictions.

Who owns APYX stock, and how is the company governed?

Apyx has one common-stock class, one vote per share and no cumulative voting. No founder or dual-class holder controls the company, although several investors have meaningful positions. Beneficial ownership includes certain options exercisable within 60 days, so it can exceed shares currently held.

What does the board structure signal?

The 2026 proxy statement identifies five directors, three of whom the board determined were independent. Charles Goodwin remains CEO and a director. Stavros Vizirgianakis became Executive Chairman in June 2026, with responsibilities spanning strategic leadership, governance, investor engagement, capital markets and corporate development. Lawrence Waldman serves as Lead Independent Director.

A dedicated Regulatory Compliance Committee is particularly relevant for a medical-device company because product quality, safety, labeling and post-market obligations can directly affect commercial continuity. Governance should therefore be judged not only by independence counts, but by how effectively the board balances growth, financing needs and regulatory discipline.

What opportunities could change Apyx Medical’s growth path?

The opportunity set is concentrated: AYON must scale in the United States, power liposuction must reach productive utilization and international Renuvion markets must expand. FY2026 guidance calls for $59 million–$60 million of total revenue, including $54 million–$55 million from Surgical Aesthetics and about $5 million from OEM. The core segment must offset planned OEM decline.

Can international expansion become a second engine?

South Korea helped Q1 2026 growth after approval of the Apyx One Console and disposable handpieces in December 2025. Renuvion launched in China in July 2025 through a distributor connected with Apyx’s 51%-owned China joint venture. The joint venture had an additional $408,000 capital commitment, of which $214,000 had been funded by March 31, 2026. International expansion can diversify U.S. procedure demand, but each market requires approval, training, distributor quality and disciplined inventory.

What risks and KPIs should researchers monitor?

Apyx’s risks are linked: slower device adoption reduces capital sales, fewer procedures reduce handpieces, weaker gross profit delays break-even, and continued losses increase financing pressure. Operating KPIs therefore matter as much as accounting results.

Which risks could weaken the outlook?

Which KPIs best explain performance?

Why does Apyx Medical matter for valuation?

Current earnings are not a stable valuation base because net income and free cash flow remain negative. A DCF must model the path to sustainable economics: AYON placements, handpiece utilization, international adoption, OEM decline, product and channel mix, tariffs and expense discipline.

Which assumptions drive intrinsic value most?

Gross-margin durability is especially sensitive at Apyx’s current size: a few percentage points materially change gross profit. The 2028 debt maturity also raises discount-rate and terminal-risk sensitivity.

What is the key takeaway from Apyx Medical analysis?

Apyx matters because it has translated a specialized helium-plasma technology into a regulated surgical-aesthetics platform with recurring consumables and a broader body-contouring system. Q1 2026 showed that AYON, international generators and handpieces can produce strong growth and operating leverage: revenue rose 32.4%, gross margin reached 63.5% and the operating loss narrowed to $0.9 million. The company also entered the quarter with $31.1 million of cash and raised FY2026 revenue guidance.

The constraint is equally clear. Apyx remains loss-making, carries a $37.5 million term loan at a 12.0% rate, faces a large 2028 principal maturity and operates against larger competitors in discretionary procedures. The quality of the story therefore depends less on headline device placements than on utilization, handpiece recurrence, gross-margin resilience, expense control and cash conversion.